Renalytix Z Score

RTNXF -  USA Stock  

USD 12.30  3.28  36.36%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Additionally, take a look at Renalytix Plc Piotroski F Score and Renalytix Plc Valuation analysis.

Renalytix Z Score 

 
Refresh

Renalytix Z Score Analysis

Renalytix Plc's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

Based on the company's disclosures, Renalytix Plc has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Diagnostics & Research industry. The z score for all United States stocks is 100.0% higher than that of the company.

Renalytix Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Renalytix Plc's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Renalytix Plc could also be used in its relative valuation, which is a method of valuing Renalytix Plc by comparing valuation metrics of similar companies.
Renalytix Plc is currently under evaluation in z score category among related companies.

Renalytix Fundamentals

About Renalytix Plc Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Renalytix Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Renalytix Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Renalytix Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Renalytix Plc without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Aroon Oscillator Now

   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at Renalytix Plc Piotroski F Score and Renalytix Plc Valuation analysis. Note that the Renalytix Plc information on this page should be used as a complementary analysis to other Renalytix Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Renalytix OTC Stock analysis

When running Renalytix Plc price analysis, check to measure Renalytix Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix Plc is operating at the current time. Most of Renalytix Plc's value examination focuses on studying past and present price action to predict the probability of Renalytix Plc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Renalytix Plc's price. Additionally, you may evaluate how the addition of Renalytix Plc to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
The market value of Renalytix Plc is measured differently than its book value, which is the value of Renalytix that is recorded on the company's balance sheet. Investors also form their own opinion of Renalytix Plc's value that differs from its market value or its book value, called intrinsic value, which is Renalytix Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renalytix Plc's market value can be influenced by many factors that don't directly affect Renalytix Plc underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renalytix Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Renalytix Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renalytix Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.